228|195|Public
25|$|Benefits {{of surgery}} include {{resection}} for a pathological diagnosis, alleviation of symptoms related to mass effect, and potentially removing disease before <b>secondary</b> <b>resistance</b> to radiotherapy and chemotherapy occurs.|$|E
25|$|The WRIM is used {{primarily}} {{to start a}} high inertia load or a load that requires a very high starting torque across the full speed range. By correctly selecting the resistors used in the <b>secondary</b> <b>resistance</b> or slip ring starter, the motor is able to produce maximum torque at a relatively low supply current from zero speed to full speed. This type of motor also offers controllable speed.|$|E
50|$|When {{primary or}} <b>secondary</b> <b>resistance</b> {{invariably}} develops, salvage therapy is considered. Allogeneic stem cell transplantation can induce durable remissions for heavily pre-treated patients.|$|E
40|$|ROTRAN 1 is a {{computer}} program to calculate the impedance and current gain of a simple transformer. Inputs to the program are primary <b>resistance,</b> primary inductance, <b>secondary</b> (load) <b>resistance,</b> <b>secondary</b> inductance, and mutual inductance. ROTRAN 1 was written in BASICA for execution on the IBM PC personal computer. It was written in 1986...|$|R
50|$|Both primary (inherent) and <b>secondary</b> (acquired) <b>resistance</b> {{has been}} {{reported}} in various lymphomas, including CLL and MCL. Resistance may arise due to mutations that impair the affinity of ibrutinib for BTK, or due to alterations in pathways downstream of BTK and may confer BCR signaling independence in resistant clones.|$|R
40|$|FLT 3 is {{the most}} {{frequently}} mutated kinase in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) in the juxta-membrane region constitute the majority of activating FLT 3 mutations. Several FLT 3 kinase inhibitors were developed and tested in the clinic with significant success. However, recent studies have reported the development of <b>secondary</b> drug <b>resistance</b> in patients treated with FLT 3 inhibitors. Since FLT 3 -ITD is an HSP 90 client kinase, we here explored if targeting the stability of drug-resistant FLT 3 mutant protein could be a potential therapeutic option. We observed that HSP 90 inhibitor treatment resulted in the degradation of inhibitor-resistant FLT 3 -ITD mutants and selectively induced toxicity in cells expressing FLT 3 -ITD mutants. Thus, HSP 90 inhibitors provide a potential therapeutic choice to overcome <b>secondary</b> drug <b>resistance</b> following TKI treatment in FLT 3 -ITD positive AML...|$|R
50|$|Surgery is {{the first}} stage of {{treatment}} of glioblastoma. An average GBM tumor contains 1011 cells, which is on average reduced to 109 cells after surgery (a reduction of 99%).Benefits of surgery include resection for a pathological diagnosis, alleviation of symptoms related to mass effect, and potentially removing disease before <b>secondary</b> <b>resistance</b> to radiotherapy and chemotherapy occurs.|$|E
50|$|Sunitinib offers {{patients}} with imatinib-resistant GIST a new treatment option to stop further disease progression and, in some cases, even reverse it. This {{was shown in}} a large, Phase III clinical trial in which patients who failed imatinib therapy (due to primary resistance, <b>secondary</b> <b>resistance,</b> or intolerance) were treated in a randomized and blinded fashion with either sunitinib or placebo.|$|E
50|$|The WRIM is used {{primarily}} {{to start a}} high inertia load or a load that requires a very high starting torque across the full speed range. By correctly selecting the resistors used in the <b>secondary</b> <b>resistance</b> or slip ring starter, the motor is able to produce maximum torque at a relatively low supply current from zero speed to full speed. This type of motor also offers controllable speed.|$|E
50|$|Windstorm {{inspections}} {{look for}} construction features {{that have been}} shown to reduce losses in hurricanes, such as a hip roof, concrete block construction, the presence of gable end bracing, shutters and opening protections, the presence of roof to wall attachments such as toe nails, clips or hurricane straps, and the presence of a <b>secondary</b> water <b>resistance</b> barrier.|$|R
40|$|There {{is growing}} {{awareness}} of <b>secondary</b> insulin <b>resistance</b> and alterations in myocardial glucose utilization in congestive heart failure. Whether therapies that directly target these changes would be beneficial is unclear. We previously demonstrated that acute blockade of the insulin responsive facilitative glucose transporter GLUT 4 precipitates acute decompensated heart failure in mice with advanced dilated cardiomyopathy. Our current objective {{was to determine whether}} pharmacologic enhancement of insulin sensitivity and myocardial glucose uptake preserves cardiac function and survival in the setting of primary heart failure. The GLP- 1 agonist exenatide was administered twice daily to a murine model of dilated cardiomyopathy (TG 9) starting at 56 days of life. TG 9 mice develop congestive heart failure and <b>secondary</b> insulin <b>resistance</b> in a highly predictable manner with death by 12 weeks of age. Glucose homeostasis was assessed by measuring glucose tolerance at 8 and 10 weeks and tissue 2 -deoxyglucose uptake at 75 days. Exenatide treatment improved glucose tolerance, myocardial GLUT 4 expression and 2 -deoxyglucose uptake, cardiac contractility, and survival over control vehicle-treated TG 9 mice. Phosphorylation of AMP kinase and AKT was also increased in exenatide-treated animals. Total myocardial GLUT 1 levels were not different between groups. Exenatide also abrogated the detrimental effect of the GLUT 4 antagonist ritonavir on survival in TG 9 mice. In heart failure <b>secondary</b> insulin <b>resistance</b> is maladaptive and myocardial glucose uptake is suboptimal. An incretin-based therapy, which addresses these changes, appears beneficial...|$|R
40|$|Based on {{the results}} of in vitro {{sensitivity}} of Plasmodium falciparum to chloroquine, quinine and mefloquine, and evaluation of drug consumption conducted in 1987 - 1988 in four areas in the noth and south-west of Cameron, two opposite situations were encountered in this country. In northern Cameron where mefloquine resistance is prevalent a close correlation was found between the responses of P. falciparum to mefloquine and to quinine, but not between mefloquine and chloroquine. In the south, where chloroquine resistance is highly prevalent, no correlation was found neither between mefloquine and chloroquine nor mefloquine and quinine, but the responses to quinine and chloroquine appear partly correlated. These lead to formulate the hypothesis of a "southern" type of P. falciparum submitted to a high chloroquine drug pressure inducing a <b>secondary</b> cross <b>resistance,</b> whilst a "northern"type submitted to a relatively high and abortive quinine drug pressure inducing a primary quinine <b>resistance</b> and a <b>secondary</b> cross <b>resistance</b> with mefloquine...|$|R
50|$|One factor {{often not}} taken into {{consideration}} when discussing CDI spark energy is the actual energy provided to the spark gap versus the energy applied to the primary side of the coil. As a simple example, a typical ignition coil may have a secondary winding resistance of 4000 ohms and a secondary current of 400 milliamperes. Once a spark has struck, the voltage across the spark gap in a running engine drops to a relatively low value, {{in the order of}} 1500-2000 volts. This, combined {{with the fact that the}} coil secondary current of 400 milliamperes loses approximately 1600 volts through the 4000 ohm <b>secondary</b> <b>resistance</b> means that fully 50% of the energy is lost in heating the coil secondary. Actual measurements show the real world efficiency to be only 35 to 38% when coil primary winding losses are included.|$|E
40|$|Background: Tyrosine kinase inhibitors (TKI) {{have emerged}} as {{important}} therapeutic agents {{for the treatment of}} several types of cancer including lung cancer. Recent research attempts show that only a small population of cancer patients responds to TKI and furthermore, these patients eventually develop resistance. Studies support the classification of resistance in primary and <b>secondary</b> <b>resistance.</b> Materials and Methods: In the present study the differentiation between primary and <b>secondary</b> <b>resistance</b> to TKI in lung cancer cell lines was investigated. Lung cancer cell lines were tested for viability, apoptosis and cell cycle after exposure to the TKI erlotinib and gefitinib. Results: Cells with primary resistance showed similar cell-cycle patterns to those with <b>secondary</b> <b>resistance</b> but differences were observed between the two groups in the viability and apoptosis assays. Conclusion: Understanding the effects of TKI on cell signaling pathways would shed light on the mechanisms of acquired resistance and the differences between primary and <b>secondary</b> <b>resistance...</b>|$|E
40|$|Nutlin {{inhibits}} TP 53 -MDM 2 {{interaction and}} {{is under investigation}} in soft-tissue sarcomas (STS) and other malignancies. Molecular mechanisms of <b>secondary</b> <b>resistance</b> to nutlin in STS are unknown. We performed whole-transcriptome sequencing (RNA-seq) on three pretreatment and secondary resistant STS cell lines selected based on their high primary sensitivity to nutlin. Our data identified a subset of cancer gene mutations and ploidy variations that were positively selected following treatment, including TP 53 mutations in 2 out of 3 resistant cell lines. Further, <b>secondary</b> <b>resistance</b> to nutlin was associated with deregulation of apoptosis-related genes and marked productive autophagy, the inhibition of which resulted in significant restoration of nutlin-induced cell death. Collectively, our findings argue that <b>secondary</b> <b>resistance</b> to nutlin in STS involved heterogeneous mechanisms resulting from clonal evolution and several biological pathways. Alternative dosing regimens and combination with other targeted agents are needed to achieve successful development of nutlin in the clinical setting...|$|E
50|$|Core {{losses are}} caused mostly by {{hysteresis}} and eddy current {{effects in the}} core and are proportional to {{the square of the}} core flux for operation at a given frequency. The finite permeability core requires a magnetizing current IM to maintain mutual flux in the core. Magnetizing current is in phase with the flux, {{the relationship between the two}} being non-linear due to saturation effects. However, all impedances of the equivalent circuit shown are by definition linear and such non-linearity effects are not typically reflected in transformer equivalent circuits. With sinusoidal supply, core flux lags the induced EMF by 90°. With open-circuited secondary winding, magnetizing branch current I0 equals transformer no-load current.The resulting model, though sometimes termed 'exact' equivalent circuit based on linearity assumptions, retains a number of approximations. Analysis may be simplified by assuming that magnetizing branch impedance is relatively high and relocating the branch to the left of the primary impedances. This introduces error but allows combination of primary and referred <b>secondary</b> <b>resistances</b> and reactances by simple summation as two series impedances.|$|R
40|$|Inhibition of RAF/MEK/ERK {{signaling}} {{is beneficial}} for many patients with BRAFV 600 E–mutated melanoma. However, primary and <b>secondary</b> <b>resistances</b> restrict long-lasting therapy success. Combination therapies are therefore urgently needed. Here, we evaluate the cellular effect of combining a MEK inhibitor with a genotoxic apoptosis inducer. Strikingly, we observed that an activated MAPK pathway promotes in several melanoma cell lines the pro-apoptotic response to genotoxic stress, and MEK inhibition reduces intrinsic apoptosis. This {{goes along with}} MEK inhibitor induced increased RAS and P-AKT levels. The protective effect of the MEK inhibitor depends on PI 3 K signaling, which prevents the induction of pro-apoptotic PUMA that mediates apoptosis after DNA damage. We could show that the MEK inhibitor dependent feedback loop is enabled by several factors, including EGF receptor {{and members of the}} SPRED family. The simultaneous knockdown of SPRED 1 and SPRED 2 mimicked the effects of MEK inhibitor such as PUMA repression and protection from apoptosis. Our data demonstrate that MEK inhibition of BRAFV 600 E-positive melanoma cells can protect from genotoxic stress, thereby achieving the opposite of the intended anti-tumorigenic effect of the combination of MEK inhibitor with inducers of intrinsic apoptosis...|$|R
40|$|The primary chemosensitivity of 16 highly {{malignant}} xenografted human soft-tissue sarcomas to ifosfamide, dacarbazine, adriamycin and cisplatin and {{the development}} of <b>secondary</b> drug <b>resistance</b> in two chemosensitive sarcoma cell lines was tested in the xenograft system. Single-dose, single-agent treatments with 350 mg kg- 1 ifosfamide, 200 mg kg- 1 dacarbazine, 10 mg kg- 1 doxorubicin and 6. 6 mg kg- 1 cisplatin were administered and response measured as specific growth delay. Since ifosfamide induced unexpectedly higher toxicity, response was corrected based on the shape of the dose-response curve for ifosfamide. Taking a specific growth delay > 3 as the cut-off point for chemosensitivity, ifosfamide, dacarbazine, doxorubicin and cisplatin were effective in 10 / 16, 4 / 16, 2 / 16 and 1 / 16 sarcoma cell lines respectively. Five out of 16 sarcoma cell lines were resistant to all tested drugs. Ifosfamide-resistant sarcoma lines were also resistant to doxorubicin and cisplatin, indicating a high degree of cross-resistance. Dacarbazine was still effective in 1 / 6 ifosfamide-resistant sarcoma cell lines. <b>Secondary</b> drug <b>resistance</b> developed slowly after doxorubicin and ifosfamide pretreatments at moderate selection pressure and developed rapidly after dacarbazine pretreatment at high selection pressure...|$|R
40|$|The {{characteristics}} of vector controlled induction motor {{system based on}} the slip 	frequency control {{are influenced by the}} variation of <b>secondary</b> <b>resistance</b> Rr with temperature. 	Therefore it is desirable that the estimated value Rr of sccondary resistance 	being used as the parameter of vector control is compensated to follow the variation. 	This paper presents a compensating method of the estimated value Rr of <b>secondary</b> 	<b>resistance.</b> The compensating method is based on the special relation which arises if 	there is a difference between Rr and Rr. This paper presents t. he simulat. ion results of 	the compensating method too...|$|E
40|$|Primary {{resistance}} to dopamine agonists occurs in 10 - 15 % of prolactinomas but <b>secondary</b> <b>resistance</b> following initial biochemical and anti-proliferative response {{is very rare}} and has only been hitherto described in four previous cases, two with bromocriptine and two with cabergoline. We describe {{a case of a}} 57 -year-old woman who presented with a large macroprolactinoma with suprasellar extension. She was initially treated with bromocriptine therapy with a resolution of symptoms, marked reduction in prolactin concentration and complete tumour shrinkage; a response which was subsequently maintained on cabergoline. After 8 years of dopamine agonist therapy, her prolactin concentration began to rise and there was symptomatic recurrence of her tumour despite escalating doses of cabergoline up to 6 mg weekly. Non-compliance was outruled by observed inpatient drug administration. The patient underwent surgical debulking followed by radiotherapy with good response. This case adds to the previous two cases of <b>secondary</b> <b>resistance</b> to cabergoline therapy in prolactinomas a marked initial response. While the mechanism of <b>secondary</b> <b>resistance</b> remains unknown and not possible to predict, close observation of prolactinoma patients on treatment is necessary...|$|E
3000|$|... [7]. Even more, EGFR-TKI was {{recently}} recommended {{to be the}} first-line therapy in EGFR-mutation positive patients with NSCLC. Unfortunately, the responsive rate to the EGFR-TKIs is low for reasons such as primary or <b>secondary</b> <b>resistance</b> [...]...|$|E
50|$|Like RCC, GIST {{does not}} {{generally}} respond to standard chemotherapy or radiation. Imatinib {{was the first}} cancer agent proven effective for metastatic GIST and represented a major development {{in the treatment of}} this rare but challenging disease. However, approximately 20% of patients do not respond to imatinib (early or primary resistance), and among those who do respond initially, 50% develop <b>secondary</b> imatinib <b>resistance</b> and disease progression within two years. Prior to sunitinib, patients had no therapeutic option once they became resistant to imatinib.|$|R
40|$|We {{report a}} case of an immunocompromised patient {{affected}} by chronic hepatitis B virus (HBV) with high basal HBV viremia (> 8 log(10)  IU/ml) who failed an entecavir regimen, {{despite the absence of}} primary or <b>secondary</b> drug <b>resistance</b> mutations. The patient achieved sustained virological success (serum HBV DNA < 12  IU/ml) when tenofovir was added to the treatment. This case highlights the difficulty in choosing an optimal therapy in such specific conditions and supports the concept of tailoring therapy (including combination regimens) {{on the basis of the}} particular conditions of each individual patient...|$|R
40|$|Background: There {{is growing}} {{awareness}} of <b>secondary</b> insulin <b>resistance</b> and alterations in myocardial glucose utilization in congestive heart failure. Whether therapies that directly target these changes would be beneficial is unclear. We previously demonstrated that acute blockade of the insulin responsive facilitative glucose transporter GLUT 4 precipitates acute decompensated heart failure in mice with advanced dilated cardiomyopathy. Our current objective {{was to determine whether}} pharmacologic enhancement of insulin sensitivity and myocardial glucose uptake preserves cardiac function and survival in the setting of primary heart failure. Methodology/Principal Findings: The GLP- 1 agonist exenatide was administered twice daily to a murine model of dilated cardiomyopathy (TG 9) starting at 56 days of life. TG 9 mice develop congestive heart failure and <b>secondary</b> insulin <b>resistance</b> in a highly predictable manner with death by 12 weeks of age. Glucose homeostasis was assessed by measuring glucose tolerance at 8 and 10 weeks and tissue 2 -deoxyglucose uptake at 75 days. Exenatide treatment improved glucose tolerance, myocardial GLUT 4 expression and 2 -deoxyglucose uptake, cardiac contractility, and survival over control vehicle-treated TG 9 mice. Phosphorylation of AMP kinase and AKT was also increased in exenatide-treated animals. Total myocardial GLUT 1 levels were not different between groups. Exenatide also abrogated the detrimental effect of the GLUT 4 antagonist ritonavir on survival in TG 9 mice...|$|R
40|$|Over {{the last}} ten years, two new-generation {{hormonal}} drugs and two chemotherapeutic agents have been approved {{for the treatment of}} metastatic castration-resistant prostate cancer. Unfortunately, some patients have primary resistance to them and the others eventually develop <b>secondary</b> <b>resistance.</b> It has recently been suggested that the presence of androgen receptor splice variants plays {{a leading role in the}} primary and <b>secondary</b> <b>resistance</b> to the new hormonal drugs, whereas their presence seem to have only a partial effect on the activity of the chemotherapeutic agents. The aim of this paper is to review the published data concerning the role of androgen receptor splice variants in prostate cancer biology, and their potential use as biomarkers when making therapeutic decisions...|$|E
40|$|International audiencePurpose We {{designed}} a gene profiling experiment to identify genes involved in secondary drug resistance in mantle cell lymphomas (MCL). Experimental Design We obtained paired tissue samples {{collected from the}} same patients before treatment and after relapse or progression. Variations in gene expression between the 2 samples were estimated for 5 patients. For each gene, the mean variation was estimated for patients with a refractory primary tumor and for responders who developed secondary drug resistance. Nine genes of interest were {{selected on the basis}} of the magnitude and statistical significance of the variation of expression in responders and non-responders. Results BMP 7 was the only one with significantly increased expression at relapse in patients who developed <b>secondary</b> <b>resistance.</b> Validation of BMP 7 as a key gene involved in <b>secondary</b> <b>resistance</b> was performed using cultures of cell line. Incubation of BMP 7 with MCL cell lines increased their resistance to bortezomib and cytarabine, while inhibition of BMP 7 expression by siRNA correlated with increased cell death linked to drug application. Conclusion Variations in gene expression after treatment point out BMP 7 as a key gene involved in <b>secondary</b> <b>resistance</b> in mantle cell lymphoma...|$|E
40|$|In {{patients}} with advanced estrogen-dependent type I endometrial cancer (EC), pharmacological treatment with progestins or antiestrogens is recommended, but primary and <b>secondary</b> <b>resistance</b> are common. The aim {{of our study}} was to investigate single-agent and dual-agent therapeutic strategies in estrogen receptor-positive human EC cells...|$|E
40|$|This is an open-access article {{distributed}} {{under the}} terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAFV 600 E–mutated melanoma. However, primary and <b>secondary</b> <b>resistances</b> restrict long-lasting therapy success. Combination therapies are therefore urgently needed. Here, we evaluate the cellular effect of combining a MEK inhibitor with a genotoxic apoptosis inducer. Strikingly, we observed that an activated MAPK pathway promotes in several melanoma cell lines the pro-apoptotic response to genotoxic stress, and MEK inhibition reduces intrinsic apoptosis. This goes along with MEK inhibitor induced increased RAS and P-AKT levels. The protective effect of the MEK inhibitor depends on PI 3 K signaling, which prevents the induction of pro-apoptotic PUMA that mediates apoptosis after DNA damage. We could show that the MEK inhibitor dependent feedback loop is enabled by several factors, including EGF receptor and members of the SPRED family. The simultaneous knockdown of SPRED 1 and SPRED 2 mimicked the effects of MEK inhibitor such as PUMA repression and protection from apoptosis. Our data demonstrate that MEK inhibition of BRAFV 600 E-positive melanoma cells can protect from genotoxic stress, thereby achieving the opposite of the intended anti-tumorigenic effect of the combination of MEK inhibitor with inducers of intrinsic apoptosis...|$|R
40|$|Our {{ability to}} detect and {{directly}} target the oncogenic alterations responsible for tumor proliferation has {{contributed significantly to the}} management of lung cancer in the last decade. The therapeutic efficacy of molecularly targeted therapy is, however, mainly limited to patients harboring certain genetic mutations and is generally short-lived. Herein, we review primary and <b>secondary</b> drug <b>resistance</b> using the most well-studied of the molecularly targeted agents, the tyrosine kinase inhibitors targeting the epidermal growth factor (EGF) receptor and the anaplastic lymphoma kinase (ALK) rearrangement, the current limitations of targeted therapies and their consequences on the management of patients with lung cancer...|$|R
40|$|Gastrointestinal stromal tumors (GISTs) are {{the most}} common mesenchymal tumors in the {{digestive}} tract characterized, in the majority of cases, by activating mutations in the KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) or PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) genes. Mutations affecting these tyrosine kinase receptors are also responsible for the mechanisms of primary and <b>secondary</b> drug <b>resistance</b> during the treatment with tyrosine kinase inhibitors. We performed mutational analysis to evaluate the pharmacotherapy susceptibility of GISTs, adopting a comprehensive procedural approach, in order to optimize the identification of mutations that may result in cellular resistance to conventional therapy...|$|R
40|$|The {{effectiveness}} of Helicobacter pylori eradication regimens {{is influenced by}} antibiotic susceptibility of infecting strains. Data concerning antibiotic resistance in children are limited. We report the evolution of primary and <b>secondary</b> <b>resistance</b> {{in a series of}} Belgian children during the last 12 years. Journal ArticleSCOPUS: ar. jinfo:eu-repo/semantics/publishe...|$|E
40|$|A history case of {{a female}} patient with {{juvenile}} idiopathic arthritis, resistant to steroids and methotrexate and <b>secondary</b> <b>resistance</b> to infliximab, is represented in this article. Switching to another tumor necrosis factor-alpha inhibitor — adalimumab — led to induction of steady remission of joint syndrome and uveitis, steroids, methotrexate and non-steroidal anti-inflammatory drugs withdrawal. </p...|$|E
40|$|Background and {{objective}} Nowadays the <b>secondary</b> <b>resistance</b> of gefitinib {{in the treatment}} of lung adenocarcinoma is an outstanding problem. This research is to explore whether the gefitinib <b>secondary</b> <b>resistance</b> can be induced by gefitinib, to explore whether epidermal growth factor receptor (EGFR) promotor methylation correlate with the gefitinib-resistance in PC 9 /GR cell lines and to find a new therapeutic target to overcome the gefitinib <b>secondary</b> <b>resistance</b> in lung adenocarcinoma. Methods In vitro cultivation of lung adenocarcinoma PC 9 cell lines, apply gefitinib on lung adenocarcinoma PC 9 cell lines, and improve drug concentration. MTT for test of gefitinib resistance index in PC 9 cell and PC 9 /GR cell. Bisulfite sequencing polymerase chain reaction (BSP) and Reverse transcription-polymerase chain reaction (RT-PCR) for detection of EGFR promoter methylation status and mRNA expression. In vitro cultivation of lung adenocarcinoma PC 9 cell lines, apply 1 μmol/L 5 -Aza-dc on lung adenocarcinoma PC 9 /GR cell lines for 72 h. MTT method for test of gefitinib resistance index in PC 9 /GR cell. Results After improving the gefitinib concentration, MTT results showed that half maximal inhibitory concentration (IC 50) of PC 9 cell lines increase from (0. 01 ± 0. 002) μmol/L to (3. 95 ± 0. 23) μmol/L (P< 0. 05). BSP results showed that abnormal methylation sites compared the degree of methylation change: PC 9 : 59 %; PC 9 /GR: 74 % (P< 0. 05). RT-PCR results showed in PC 9 /GR cell lines, EGFR mRNA expression quantity increased (P< 0. 05). After applying 5 -Aza-dc on PC 9 cell lines, IC 50 of PC 9 /GR decrease from (3. 87 ± 0. 034) μmol/L to (2. 55 ± 0. 14) μmol/L. Conclusion The PC 9 cell line which is induced by improving gefitinib concentration will be resistant to gefitinib, and the gefitinib-resistant cell line PC 9 /GR could be built. EGFR gene promoter methylation {{may be one of the}} mechanisms for the <b>secondary</b> <b>resistance</b> to gefitinib...|$|E
40|$|Using {{electron}} microscopy, {{a closed}} circular form of DNA (4. 3 mum in contour length) was {{detected in the}} nucleus of mouse embryo fibroblasts 2. 5 h after infection by Rauscher murine leukemia virus. These circles were distinguishable from mitochondrial DNA by various criteria, including size, absence of <b>secondary</b> features, and <b>resistance</b> to EcoRI endonuclease...|$|R
40|$|Acquisition of <b>resistance</b> <b>secondary</b> to {{treatment}} both by microorganisms and by tumor cells {{is a major}} public health concern. Several species of bacteria acquire resistance to various antibiotics through stress-induced responses that have an adaptive mutagenesis effect. So far, adaptive mutagenesis in yeast has only been described when the stress is nutrient deprivation. Here, we hypothesized that adaptive mutagenesis in yeast (Saccharomyces cerevisiae and Candida albicans as model organisms) would also take place in response to antifungal agents (5 -fluorocytosine or flucytosine, 5 -FC, and caspofungin, CSP), giving rise to <b>resistance</b> <b>secondary</b> {{to treatment}} with these agents. We have developed a clinically relevant model where both yeasts acquire resistance when exposed to these agents. Stressful lifestyle associated mutation (SLAM) experiments show that the adaptive mutation frequencies are 20 (S. cerevisiae – 5 -FC), 600 (C. albicans – 5 -FC) or 1000 (S. cerevisiae – CSP) fold higher than the spontaneous mutation frequency, the experimental data for C. albicans – 5 -FC being {{in agreement with the}} clinical data of acquisition of <b>resistance</b> <b>secondary</b> to treatment. The spectrum of mutations in the S. cerevisiae – 5 -FC model differs between spontaneous and acquired, indicating that the molecular mechanisms that generate them are different. Remarkably, in the acquired mutations, an ectopic intrachromosomal recombination with an 87 % homologous gene takes place with a high frequency. In conclusion, we present here a clinically relevant adaptive mutatio...|$|R
40|$|Massively {{parallel}} sequencing {{fails to}} detect minor sue samples prior to resistance mutations of the recurrent tumours. This supports {{the theory that}} <b>secondary</b> KIT <b>resistance</b> mutations Heydt et al. BMC Cancer (2015) 15 : 291 DOI 10. 1186 /s 12885 - 015 - 1311 - 0 Cologne, Germany Full list of author information {{is available at the}} end of the articledevelop under treatment by “de novo ” mutagenesis. Alternatively, the detection limit of two mutated clones in 10, 000 wild-type clones might not have been high enough or heterogeneous tissue samples, per se, might not be suitable for the detection of very small subpopulations of mutated cells...|$|R
